Zenzedi has been recalled after a pill mix-up.Photo:FDA

FDA
A medication that’s used to treat ADHD and narcolepsyhas been recalledafter other pills were found in a bottle of the drug.
The Food and Drug Administration announced manufacturer Azurity Pharmaceuticals’ voluntaryrecallWednesday, saying “a pharmacist in Nebraska … opened a bottle of Zenzedi 30 mg tablets and found tablets of Carbinoxamine Maleate, an antihistamine drug.”
However, the antihistamine found in the bottle “has sedative properties,”the National Institute of Health says.
A bottle of Zenzedi.FDA

And as the FDA warns in its recall notice, “there is a reasonable probability that accidents or injuries that occur due to the sedating effects of carbinoxamine, could lead to ongoing disability or death in severe cases, particularly if individuals who use it (unaware that they have not received Zenzedi) engage in activities requiring significant focus and alertness (e.g., driving, operating heavy machinery).”
The two drugs do look vastly different, with Zenzedi being a yellow hexagonal pill with “30” on one side, and “MIA” on the other. The Carbinoxamine Maleate tablets found in the bottle of the stimulant were white and round, with “GL” on one side and “211” on the other.
The recalled Zenzedi has the lot number F230169A, with a June 2025 expiration date.
The United States isstill experiencing a shortageof medication for ADHD, the more common abbreviation for Attention Deficit Hyperactivity Disorder, which “includes a combination of persistent problems, such as difficulty sustaining attention, hyperactivity and impulsive behavior,” the Mayo Clinic explains.
Zenzedi is small and yellow.FDA

Not taking ADHD stimulant medication regularly “can lead to withdrawal while also increasing ADHD symptoms,”Verywell Mindwrote.
However, at the time of the FDA’s announcement, no “serious adverse events related to this recall” have been reported.
Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
source: people.com